Supernus Pharmaceuticals (SUPN) stock had its Relative Strength (RS) Rating upgraded from 77 to 86 Thursday.
Looking For The Best Stocks To Buy And Watch? Start Here
IBD's proprietary rating tracks share price performance with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history shows that the market's biggest winners typically have an RS Rating of at least 80 as they launch their biggest price moves.
Supernus Pharmaceuticals stock is within a buy zone after moving past a 40.28 entry in a cup without handle. The proper buying range extends to 5% above the initial entry. Once a stock moves above that range, it's best to wait for it to set up another buying opportunity.
Earnings growth increased last quarter from 0% to 11%. But sales fell from 4% to -2%.
Supernus Pharmaceuticals stock holds the No. 53 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals (AUPH), Rigel Pharmaceuticals (RIGL) and Incyte (INCY) are among the top 5 highly rated stocks within the group. For industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
YOU MAY ALSO LIKE:
MarketSurge's Tools Can Help The Individual Investor
IBD Live: A New Tool For Daily Stock Market Analysis
Profit From Short-Term Trends With SwingTrader
How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。